Literature DB >> 33788729

Expression Patterns of ERα, ERβ, AR, SIRT1, SIRT2, and SIRT3 in Prostate Cancer Tissue and Normal Prostate Tissue.

Jae Hwi Choi1, See Min Choi1,2,3, Sin Woo Lee1, Seong Uk Jeh1,2,3, Jae Seog Hyun1,2,3, Min Ho Lee4, Chunwoo Lee4, Sung Chul Kam2,3,4, Dong Chul Kim2,3,5, Jong Sil Lee2,3,5, Jeong Seok Hwa6,2,3.   

Abstract

BACKGROUND/AIM: The purpose of this study was to examine the expression of estrogen receptor α (ERα) and β (ERβ), androgen receptor (AR), SIRT1, SIRT2 and SIRT3 in prostate cancer (PCa).
MATERIALS AND METHODS: From October 2010 to January 2015, 70 patients who had undergone radical prostatectomy following a PCa diagnosis were enrolled in our study. Normal prostate tissue (NPT) and prostate cancer tissues (PCAT) were separated, and the expression of each receptor in each tissue was analyzed with immunochemical staining. Univariate and multivariate analyses were performed to identify factors affecting the development of PCa.
RESULTS: ERβ and AR were highly expressed in PCAT compared with NPT (p<0.05). SIRT2 was highly expressed in NPT and PCAT (p<0.05). Univariate and multivariate analyses showed that AR and SIRT2 affect PCa development.
CONCLUSION: AR is a risk factor for PC, and SIRT2 is associated with a lower incidence of PCa.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  SIRT1; SIRT2; SIRT3; the androgen receptor; α estrogen receptor; β estrogen receptor

Mesh:

Substances:

Year:  2021        PMID: 33788729     DOI: 10.21873/anticanres.14895

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  HSA-miR-34a-5p regulates the SIRT1/TP53 axis in prostate cancer.

Authors:  Yongqin Wen; Huijie Huang; Bo Huang; Xiaomin Liao
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  Variants in HOXB13, G132E and F127C, Are Associated With Prostate Cancer Risk in Japanese Men.

Authors:  Sota Kurihara; Hiroshi Matsui; Nobuaki Ohtake; Masanori Aoki; Yoshitaka Sekine; Seiji Arai; Hidekazu Koike; Kazuhiro Suzuki; Yoshiyuki Miyazawa
Journal:  Cancer Diagn Progn       Date:  2022-09-03

Review 3.  Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment.

Authors:  Dali Tong
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.